Oxazepam

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Oxazepam

Examples of brand names: Adumbran [DE]

ATC code: N05BA04

Main use (for orientation): Anxiety; withdrawal syndromes

Documented research summary

CBD and THC inhibit oxazepam glucuronidation stereoselectively in vitro. The model predicts higher AUC with oral CBD at 700/2000 mg; for THC, only the highest modelled oral dose in the R-isomer scenario narrowly reaches the signal threshold. No clinically measured increase in oxazepam concentrations or clinically established dose threshold.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0105

Type of result: Context-specific finding; read the limitations

Observation: R/S glucuronidation inhibited in the laboratory.

Mechanism: Stereoselective UGT inhibition

Study type: In vitro and static in-vitro–in-vivo extrapolation (IVIVE)

Context studied: Recombinant UGT, human liver/kidney microsomes; R and S enantiomers assessed separately.

Clinical interpretation: Clinical effect not determined

Limitations and uncertainties: Do not infer clinical sedation or a dose change from this experiment.

Original sources for this finding: Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid–Oxazepam Drug Interactions [ME09]

THC – laboratory and animal studies

Finding ID: B0106

Type of result: Context-specific finding; read the limitations

Observation: Oxazepam glucuronidation inhibited in the laboratory.

Mechanism: Stereoselective UGT inhibition

Study type: In vitro and static in-vitro–in-vivo extrapolation (IVIVE)

Context studied: THC and metabolites investigated; stereoisomer dependence.

Clinical interpretation: Clinical effect not determined

Limitations and uncertainties: No combination tested in patients.

Original sources for this finding: Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid–Oxazepam Drug Interactions [ME09]

References and access status

[C_LABEL_D0067] OXAZEPAM CAPSULE [EPIC PHARMA, LLC]

Original source / bibliographic reference

Authors: EPIC PHARMA, LLC

Year: 2025

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[ME09] Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid–Oxazepam Drug Interactions

Original source / bibliographic reference

Authors: Bardhi K; Coates S; Chen G; Lazarus P

Year: 2024

Source type: Original study: in-vitro UGT and IVIVE

DOI: 10.3390/pharmaceutics16020243

PMID: 38399297

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility